OmniAb SPAC Presentation Deck

SETTING THE STAGE - OMNIAB'S SPIN-OFF FROM LIGAND • Ligand's proven business model is focused on developing and acquiring technologies that enable the discovery and development of medicines ● 400+ fully-funded programs in various stages 1,600+ issued patents worldwide On November 9, 2021, Ligand announced its intention to split into two separate, publicly-traded companies - 140+ partners among pharmaceutical and biotechnology companies SpinCo: OmniAb, Icagen and other antibody discovery technologies - RemainCo: Core existing royalties and Captisol, Pelican technologies Anchored tax-free spin-off to create two well-capitalized companies Operational focus Business-specific capital allocation Agility to meet partner needs Opportunity to unlock value of OmniAb Ligand at a Glance Broad portfolio of 140+ different partners PELICAN P. Hluorescens expression technology CAPTISOL Discovery Preclinical Phase 1 Phase 2 Phase 3 Registration Approved Approved Registration Phase 3 Phase 2 Phase 1 Preclinical Discovery PROPRIETARY COMPOUNDS Note: Each dot in above graphic represents a program 10 OmniAb OmniAb

View entire presentation